Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for attenuating parasite virulence

A technology of parasites and malaria parasites, applied in the direction of pharmaceutical formulations, organic active ingredients, and resistance to vector-borne diseases, etc., can solve problems affecting the infection process and disease onset process

Inactive Publication Date: 2018-08-28
药物分子研究所
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, the following paragraphs describe a novel approach to malaria treatment that exploits the mechanisms used by the Plasmodium parasite to rapidly regulate nutrient fluctuations in a manner that has a dramatic effect on its virulence, thereby affecting the course of infection and the course of disease onset.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for attenuating parasite virulence
  • Methods for attenuating parasite virulence
  • Methods for attenuating parasite virulence

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0038] Example 1 Host feeding affects survival and parasite load. C57BL / 6 mice (5-8 weeks old, body weight 20-28 g) were allowed free access to water and food, or placed in a calorie restricted (CR) group. Mice in the CR group were given 60-70% of the food per day relative to the food consumed by the ad libitum control group (AL). Food intake in both groups was measured once a day, and body weight was measured at least 3 times a week. When 15–20% body weight loss is achieved, adjust the daily food amount allocated to CR mice or rats to stabilize lower body weight for the remainder of the experimental period. By intradermal (i.d.) injection of 5 x 10 3 Freshly dissected Plasmodium berghei sporozoites ( figure 2 ) or by intraperitoneal (i.p.) injection of 10 6 Plasmodium berghei-infected erythrocytes were used to infect mice, and Plasmodium berghei-infected erythrocytes were obtained from the previous passage of C57BL / 6 mice ( image 3 ). House 3-5 mice per cage.

[0039...

example 2

[0040] Example 2 AMPK activating compounds mimic CR-mediated AMPK activation. Western blot analysis of AMPK phosphorylation in liver homogenates from uninfected C57BL / 6 mice in the AL and DR fed groups and uninfected mice one hour after salicylate or vehicle injection, see Figure 4 . The liver was dissolved in ice-cold lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM sodium pyrophosphate, 0.5 mM EDTA, 1 mM DTT, 1% octylphenol polyethylene glycol ether (triton), 1 mM Na 3 VO 4 , 250mM sucrose, protease inhibitor cocktail and phosphatase inhibitor). The total protein content in each homogenate was measured by the Bradford Assay (Bio-Rad) according to the manufacturer's instructions. Dissolve 50 μg of total liver lysate on 8% SDS-PAGE or Any kD TM Precast gels (Bio-Rad) and transferred to nitrocellulose membranes using a standard wet transfer with 1× Tris-glycine buffer (containing 20% ​​methanol) at a constant voltage of 100 V for 2 hours, or using Gel Transfer S...

example 3

[0042] Example 3 Reduction of Plasmodium liver stage infection by AMPK activating compounds. 72 hours post infection h.p.i. of C57BL / 6 mice infected with freshly dissected P. Relative parasitaemia in C57BL / 6 mice was analyzed by flow cytometry (as described in Example 1). One hour before infection, salicylate (300 mg / Kg, Sigma No. 71945) was administered once daily by intraperitoneal injection. Metformin (500 mg / Kg, Sigma No. D150959) was provided in drinking water one week before and during infection. see results Figure 5 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Pharmaceutical compositions and methods for the treatment of malaria are presented. Such compositions and methods may target energy-sensing pathways of the malaria parasite, Plasmoclium, of parasite host cell, or both. The compositions, in certain aspects of the present invention, target a signalling pathway involving the host AMP-protein activated kinase (AMPK) and / or the parasite AMPK homologue,KIN, which controls parasite replication and virulence.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Application No. 62 / 234,808, filed September 30, 2015, and US Application No. 62 / 234,811, filed September 30, 2015. technical field [0003] An energy-dependent mechanism for attenuating intracellular parasite proliferation. Background technique [0004] Parasites need a host to survive. Therefore, they must also have mechanisms to sense and respond to the nutritional status of their hosts, which not only determines the availability of nutrients but also reflects the quality and viability of the host environment. Plasmodium, the causative agent of malaria, is a rapidly multiplying protozoan parasite that undergoes a complex developmental life cycle in vertebrate and mosquito hosts. In mammalian blood, Plasmodium parasites invade and replicate by dividing within red blood cells (RBCs), producing 10-30 new merozoites every 1-3 days, depending on the species. The continuous cycle o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/155A61P33/06
CPCA61K31/155A61P33/00A61K31/05A61K31/60Y02A50/30
Inventor L·M·席尔瓦M·M·迪亚斯莫塔
Owner 药物分子研究所